Cargando…

Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease

BACKGROUND: The need for individualized treatment regimens is becoming more important in the management of patients with inflammatory bowel disease (IBD). Gastroenterologists may dose adjust either by increasing the dose or shortening the dosing interval from the initial recommended maintenance dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehrenberg, Rahel, Griffith, Jenny, Theigs, Cindy, McDonald, Bryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391226/ https://www.ncbi.nlm.nih.gov/pubmed/32191593 http://dx.doi.org/10.18553/jmcp.2020.19388

Ejemplares similares

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer
por: Devlin, Lynsey, et al.
Publicado: (2022)

Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis()
por: Fender, Anke C., et al.
Publicado: (2020)

Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2020)

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment
por: Marotti, Valentina, et al.
Publicado: (2023)

Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease
por: Ancona, Silvana, et al.
Publicado: (2023)

Epithelial-microbial diplomacy: escalating border tensions drive inflammation in inflammatory bowel disease
por: King, Stephanie J, et al.
Publicado: (2019)

Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
por: Hirakawa, Akihiro, et al.
Publicado: (2019)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

The Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function
por: Prentice, Ralley E., et al.
Publicado: (2023)

Economic Burden of Fatigue in Inflammatory Bowel Disease
por: Ananthakrishnan, Ashwin N, et al.
Publicado: (2023)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Plants and Plant-Derived Molecules as Natural Immunomodulators
por: Zebeaman, Meseret, et al.
Publicado: (2023)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2021)

Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-biotics in Inflammatory Bowel Disease
por: Russo, Edda, et al.
Publicado: (2019)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
por: Shewalkar, Balaji, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Systematic review with meta‐analysis: the effects of immunomodulator or biological withdrawal from mono‐ or combination therapy in inflammatory bowel disease
por: Dohos, Dóra, et al.
Publicado: (2020)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upq279nigslsi76cm3cnfarqb5